Breath Therapeutics Holding BV
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Breath Therapeutics Holding BV
Finance Watch: iTeos, Pandion And Aspen Show COVID-19 Hasn’t Slowed VC Deals Yet
Aspen Neuroscience, Pandion and iTeos raised $70m, $80m and $125m, respectively. Also, Glide Healthcare closed a €416m ($450m) fund; ElevateBio, Kallyope and SutroVax reveal VC mega-rounds; and Dragonfly adds new funding to its partnering proceeds.
Deal Watch: Celgene Reworks Alliance With Jounce, Gaining Global Rights To Macrophage-Targeting Candidate
Revised agreement of 2016 collaboration returns all vopratelimab rights to Jounce. Gilead fortifies antiviral pipeline in deals with Novartis, Durect.
Breath Therapeutics Snapped Up Post Series A By Specialty Company Zambon
Italy’s privately held Zambon could pay up to €500m to bulk up its respiratory products pipeline, producing a nice return for Breath Therapeutics’ syndicate of European investors.
Value-Added Respiratory Round-Up: Cipla Teams With Pulmatrix For Itraconazole
Cipla has struck a deal for dry-powder itraconazole and has also launched a fine-particle beclometasone/formoterol inhaler in India.
- Other Names / Subsidiaries
- Breath Therapeutics GmbH (BREATH)
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.